Search
for
Sort by
Research 181–210 of 457
- Potential applications of topical oxygen therapy in dermatology
- Aesthetics and Rejuvenation of the Temple
- Spironolactone May Reduce the Risk of Incident Rosacea
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Hyperdiluting Calcium Hydroxylapatite With Platelet-Rich Plasma and Hyaluronidase for Improving Neck Laxity and Wrinkle Severity
- Reliability and Validity of a Photographic Method for Measuring Facial Hair Density in Men
- Determination of Minoxidil by Bleaching the Permanganate Carrier Solution in a Flow-Based Spectrophotometric System
- Potentiometric determination of Minoxidil in topical use pharmaceutical samples
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Hyaluronic Acid Filler Injection as an Alternative to Surgery for the Correction of Canine Entropion
- Nonpigmented hair removal using photodynamic therapy in animal model
- Quoi de neuf en recherche dermatologique ?
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Safety and Effectiveness of a Novel Hyaluronic Acid Gel for Lip Augmentation
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
- Decoding Hyperpigmentation from Biological Mechanisms to Actives with Clinically Proven Topical Efficacy: A Narrative Review
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
- Use of Castor Oil in Dermatology: A Narrative Review
- Scalp cooling and chemotherapy-induced alopecia: Evaluating cost-effectiveness and insurance coverage
- Gender based price differences in 5% minoxidil foam: The impact of generic alternatives and bulk packaging
- Expert Perspectives: Evidence-Based Applications of Polynucleotides (PNs) in Aesthetic Medicine and Dermatology
- Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study